AstraZeneca PLC vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.5
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
AZN
High-quality business with 23% return on equity and 17% profit margins.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $223.79 (+21.1%)
10 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
AZN
MRK
27.9×
Trailing P/E
31.5×
23.7×
Forward P/E
11.5×
17.2%
Profit Margin
13.6%
81.5%
Gross Margin
76.6%
23.5%
ROE
—
12.5%
Revenue Growth
4.9%
5.3%
Earnings Growth
—
0.28
Beta
0.28
—
Price / Book
—
$286.4B
Market Cap
$277.0B
$132 – $213
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →